A major advantage of the Cet-ZA ADC towards other drug formulations, including ZA-SPN, is the ability to select, activate and drive an anti-tumor effector cell population into the tumor, due to the specificity of the anti-EGFR Cet, not only avoiding other localizations of ZA, but also targeting only EGFR+ cells, either CRC cells or CRC-TAF. This evidence concerns the gene EGFR and neoplasm.